問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

更新時間：2023-09-19

黃俊升Huang, Chiun-Sheng
  • Principal Investigator
  • Clinical Trial Experience (year) -24 years -4 個月

Recruiting Trial

37Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃俊升

List

91Cases

2017-03-01 - 2019-12-31

Phase III

Completed
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

  • Condition/Disease

    Triple Negative Breast Neoplasms

  • Test Drug

    學名：Pembrolizumab (MK-3475) ；商品名：KEYTRUDA®/吉舒達®

Participate Sites
6Sites

Terminated6Sites

陳訓徹
Linkou Chang Gung Medical Foundation

劉峻宇
Taipei Veterans General Hospital

Division of Hematology & Oncology

2023-10-01 - 2033-02-05

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2023-11-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2024-08-15 - 2026-12-31

Others

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting5Sites

Recruiting4Sites

2024-10-15 - 2025-10-31

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-02-28 - 2032-06-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2025-06-01 - 2025-11-03

Phase III

Not yet recruiting
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting11Sites

2025-10-31 - 2029-02-04

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting5Sites

2021-06-01 - 2031-12-24

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2023-06-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2 3 4 5 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB